Repligen to Announce Fourth Quarter and Full Year 2024 Financial Results

WALTHAM, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) has announced that it will release its financial results for the fourth quarter and the full year 2024 on Thursday, February 20, 2025. The company will provide a press release before the market opens to share its financial performance.

A conference call will follow the release at 8:30 a.m. ET, where Repligen will discuss both business updates and financial results for the reporting periods that ended on December 31, 2024.

The conference call can be accessed by domestic callers at the toll-free number (844) 274-3999 and by international callers at (412) 317-5607. No passcode is necessary for participants. Additionally, a webcast will be available on the Investor Relations section of Repligen's website. For those unable to join live, both the conference call and the webcast will be archived. Replay options include the following dial-in numbers: (877) 344-7529 for U.S. callers, (855) 669-9658 for Canadian callers, and (412) 317-0088 for international callers. Please note that a passcode of 6188777 is required to access the replay.

About Repligen Corporation

Repligen Corporation is a global life sciences enterprise that specializes in the development and commercialization of advanced bioprocessing technologies and systems. These innovations facilitate greater efficiency in the manufacturing of biological drugs. The company is driven by the mission of "inspiring advances in bioprocessing" for its clients, which primarily include biopharmaceutical developers and contract development and manufacturing organizations (CDMOs) worldwide. Repligen focuses on several key areas, including Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. The corporate headquarters are located in Waltham, Massachusetts, with the majority of manufacturing facilities situated in the United States, alongside additional key sites in Europe, including Estonia, France, Germany, Ireland, the Netherlands, and Sweden. For more information, visit their website at www.repligen.com and connect with them on LinkedIn.

This press release includes forward-looking statements in line with federal securities laws. Investors should be aware that these statements, indicated by terms such as "believe," "expect," "may," "will," "should," and similar terms, represent forward-looking statements. These statements are subject to various risks and uncertainties that could result in actual outcomes differing significantly from those anticipated, including risks outlined in the company's filings with the Securities and Exchange Commission. The company disclaims responsibility for updating forward-looking statements unless legally obligated to do so.

Contact Information:

Sondra S. Newman

VP, Global Head of Investor Relations

(781) 419-1881

[email protected]

Repligen, Earnings, 2024